Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. The Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido completed. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

Market Cap	$20.41M	P/E Ratio	NaN
52W High	$5.95	52W Low	$0.65
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	-1.3%	52W Position	8.9%
Overall Score	32	Value Score	60
Quality Score	26	Technical Score	10

EPS Current Est	$NA	EPS Next Est	$NA
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CTXR	$1.12	-3.45%	192.46K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CTXR	$1.12	-3.4%	192.46K
3
4
5
6

CTXR

CTXR

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Citius Pharmaceuticals Inc. Data in Excel

Get Citius Pharmaceuticals Inc. Data in Excel